HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Sales & Earnings In Brief

This article was originally published in The Rose Sheet

  • News

Executive Summary

Beiersdorf “Not Satisfied” With 2010

You may also be interested in...



Analyst: Outsider Heidenreich Brings Fresh Perspective As Beiersdorf CEO

Beiersdorf AG’s surprise move to name Stefan F. Heidenreich CEO in place of Thomas-B. Quaas will give the firm a competitive boost, according to analyst Andrew Wood of Bernstein Research.

Outlook Is Cheery For Designer Fragrances This Holiday Season – NPD

This holiday season, designer fragrances are expected to compete more effectively against similarly priced electronics than they have in recent years, according to NPD Group Vice President and Global Industry Analyst Karen Grant.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Table

View full table

Tags:
Latest Headlines

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

Cosmetic And Personal Care Trademark Review: 16 April

Health And Wellness Weekly Trademarks Review: 16 April

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

See All
UsernamePublicRestriction

Register

RS017398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By